SGMO
Sangamo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.07
+0.00%Margins
Gross margin
100.0%
EBITDA margin
-339.9%
EBIT margin
-319.2%
Net margin
-356.9%
FCF margin
-261.8%
650.6%
Return on equity
-205.7%
Return on assets
—
Return on invested capital
0.58x
Asset turnover
-$90.3M
Cash from operations
$0.07
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026